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MEETING SUMMARY
This educational symposium, sponsored by Britannia Pharmaceuticals Limited, was held during the 1st
Congress of the European Academy of Neurology (EAN), which took place from 20th-23rd June 2015 in
Berlin, Germany. The symposium reviewed the role of non-oral drug delivery strategies in patients with
Parkinson’s disease (PD) and how they can overcome problems that occur with the gastrointestinal (GI)
route of administration in many patients. GI dysfunction is recognised as a common problem in PD and
may in fact be a preclinical marker of the disease. It can affect the absorption of oral medication
resulting in OFF periods and unreliable control of motor symptoms, which in turn can have a negative
impact on quality of life (QoL). Delayed time-to-ON (TTO) after an oral levodopa dose and dose
failures are known to be significant contributors to total OFF time. Results of the recently completed
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AM-IMPAKT trial in patients with morning akinesia due to a delay in the onset of oral levodopa effect
demonstrate that apomorphine intermittent injection (penject) is able to provide rapid and effective
resolution of such complications, restoring patients to the ON state quickly and allowing them to get on
with their daily activities.

Gastrointestinal Dysfunction in
Parkinson’s Disease
Professor Werner Poewe

PD reported the presence of NMS. They occurred
across all disease stages and many patients
experienced multiple symptoms – the mean number
of NMS per patient in the survey was 7.8. Notably,
GI symptoms were present in 45% of newly
diagnosed, untreated patients, 60% of those with
stable disease, and 72% of those with complex
disease (Figure 1).

Prof Poewe reminded delegates that while PD
is traditionally considered to be primarily a
movement disorder, it is in fact a multi-system
disease and affects areas of the brain that are not
directly involved in motor control, for example the
hypothalamus, locus coeruleus, and raphe nuclei
of the brainstem.1-3 PD pathology also extends into
the peripheral autonomic nervous system involving
sympathetic ganglia, cardiac sympathetic efferents,
and the enteric nervous system (ENS).
The PRIAMO study4 was a multicentre survey
that interviewed 1,072 consecutive PD patients
at different stages of disease (treatment-naïve,
stable, and complex) over a period of 12 months at
55 centres in Italy to assess the prevalence of nonmotor symptoms (NMS) in PD and their impact on
QoL. The results found that 98.6% of patients with

Prof Poewe commented that, in many cases, if
patients were not specifically asked about
these symptoms, they might be overlooked. He
highlighted the results of a study of 89 PD patients
who undertook a validated NMS questionnaire
(NMSQ), which was compared with standard
neurology clinic reporting in case notes.5 Results of
NMSQ found a mean of 11 different NMS per patient.
In contrast, chart review showed a mean of 4.8
NMS per patient, suggesting that some symptoms
remain under-reported by patients unless
questioned. In this study, constipation was reported
by 48%, highlighting that GI problems are a
frequent non-motor issue in PD.
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Figure 1: Prevalence of non-motor Parkinson’s disease symptoms in patients with treatment-naïve,
stable, and complex disease: results of the PRIAMO study.4
Reproduced with permission of Movement Disorders.
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Figure 2: Levodopa dose is predictive of the development of dyskinesia and wearing-off: results of the
STRIDE-PD study.17
*Rates at study termination.
Reproduced with permission of Movement Disorders.

GI dysfunction in PD patients is now known to
occur at all levels of the GI tract.6,7 Common clinical
features include sialorrhoea (drooling), dysphagia,
gastroparesis, colonic dysmotility (constipation),
and anorectal dysfunction. These symptoms have
a range of clinical consequences for patients, and
in some cases can be a burden for their caregivers
too, resulting in social embarrassment, reduced
appetite, weight loss, aspiration of food, and impact
on effective absorption of oral PD medication.
It is now recognised that development of NMS
can precede the onset of motor symptoms in PD.
A recent study was undertaken to investigate the
timing of onset of NMS in PD and the possible
association with motor phenotype using a custommade questionnaire in 109 newly diagnosed,
untreated PD patients and 107 age and sexmatched healthy controls from 11 centres in Spain
and Austria.8 Seventeen of 31 different NMS were
found to be more common in PD patients than in
controls (p<0.05). Notably, in >50% of PD patients,
NMS preceded the onset of motor symptoms.
The symptoms reported more frequently in the
2-10-year premotor period were smell loss, mood
disturbances, taste loss, excessive sweating, fatigue,
and pain. Constipation, dream-enacting behaviour,
excessive daytime sleepiness, and postprandial
fullness were frequently perceived more than
10 years before motor symptoms occurred.
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The natural history of PD is characterised by a
gradual decline in striatal dopamine through
the preclinical and prodromal stages, eventually
reaching an 80% deficit which is indicative of
a diagnosis of PD and represents a 50% loss of
neurons in the substantia nigra. The identification
and characterisation of prodromal NMS of PD is
the subject of considerable research. In the case of
GI dysfunction, studies by Abbott and colleagues9
found that constipation and infrequent bowel
movements were associated with a significantly
elevated risk of future PD (p=0.005). Further
studies by this group found evidence that
constipation can predate the extrapyramidal signs
of PD and could be one of the earliest markers of
the beginning of the PD process. The preclinical
phase of PD is often characterised by the presence
of incidental Lewy bodies (ILB). Assessment of
bowel movement frequency in 245 men, aged
71-93 years without clinical evidence of PD who later
received post-mortem examinations, found that
the percentage of brains with ILB declined with
increasing bowel movement frequency (p=0.013).10
There is a substantial need for an accurate early
diagnostic test for PD, and with this in mind,
researchers have been focussing on the potential
link between ENS pathology and preclinical or
prodromal PD. Alpha-synuclein is the primary
structural component of Lewy bodies and its
aggregation is thought to play a critical role in the
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development of PD. Alpha-synuclein pathology
has been found in body tissues outside of the brain
not usually associated with PD. A recent study has
suggested that alpha-synuclein may be present in
colonic biopsy tissue in early or even prodromal
PD before the development of characteristic PD
motor symptoms, and may therefore be a potential
diagnostic biomarker for pre-motor PD.11 Archival
colon biopsy samples obtained 2-5 years before
PD onset were analysed for three patients with
PD. All patients showed immunostaining for alphasynuclein at least 2 years before the first motor PD
symptom occurred. In contrast, no corresponding
alpha-synuclein immunostaining was seen in
23 healthy controls.
Prof Poewe concluded by highlighting that many
aspects of GI dysfunction in PD are now recognised
to have a significant potential impact on oral drug
delivery and hence clinical efficacy.12 Difficulties
in swallowing can lead to adherence problems in
patients receiving oral medication. Delayed gastric
emptying (gastroparesis) can lead to a reduction
in the speed of oral levodopa delivery to its site
of absorption in the small intestine, resulting in a
‘delayed ON’ or even dose failure. Competition
between levodopa and proteins for transport
across the GI mucosa can result in unpredictable
drug responses. The OFF periods that the
patient experiences will result in motor and nonmotor fluctuations that have a negative impact
on their QoL, and so Prof Poewe considered
that it was important that alternative therapeutic
interventions were sought in such cases.

series of patient videos. In addition to classical motor
fluctuations, many PD patients also experience
non-motor fluctuations, such as anxiety, panic
attacks, pain, fatigue, mood changes, urinary
urgency, and swallowing difficulties.14
Wearing-off is commonly associated with the
later stages of PD. However, a review of preclinical
and clinical data suggest that fluctuations in the
response to levodopa may appear much earlier than
previously thought, and can be present in patients
with early disease.15 Prof Stocchi presented the
results of the DEEP study (Early DEtection of
wEaring off in Parkinson disease),16 which was
undertaken to assess the frequency of wearing-off
in PD patients and its impact on QoL using a
validated screening tool, WOQ-19. These results
showed that the frequency of wearing-off
increased with duration of disease such that, after
10 years, around 80% of PD patients experienced
wearing-off phenomena.

Professor Fabrizio Stocchi

Prof Stocchi went on to highlight some of the risk
factors underlying complications in PD. He reviewed
a secondary analysis of the STalevo Reduction
In Dyskinesia Evaluation in Parkinson’s Disease
(STRIDE-PD) study that had investigated the effect
of levodopa dose and other risk factors on the
development of dyskinesias and wearing-off. The
results demonstrated that time to development
of dyskinesias and time to wearing-off both
correlated with the dose of oral levodopa
(Figure 2).17 Multivariate analyses showed that
factors predictive of dyskinesia included young age
at onset, higher levodopa dose, low body weight,
female gender, and more severe Unified Parkinson’s
Disease Rating Scale (UPDRS) Part III scores.
Predictors of wearing-off included higher baseline
UPDRS scores, higher levodopa dose, and the
female gender.

Prof Stocchi described how ‘ON–OFF’ fluctuations
in PD patients receiving chronic oral levodopa
therapy were first described by Marsden and Parkes
in 1976.13 Motor complications include both motor
fluctuations and dyskinesias. Motor fluctuations
can include predictable end-of-dose ‘wearingoff’ phenomena, peripheral problems such as
delayed ON (for example morning akinesia) or
‘no ON’ (dose failure), and unpredictable ON–OFF
periods. Dyskinesias may be peak-dose effects,
distressing and painful diphasic dyskinesias, or
painful OFF-period dystonia. He highlighted how
debilitating and distressing these different motor
complications can be in the real-life setting with a

Motor complications in PD patients are recognised
to have a significant impact on QoL.18 This was
investigated in 143 patients with PD who were
evaluated using the Hoehn and Yahr scale and the
motor part of the UPDRS. In addition, a specific
PD QoL questionnaire (39-item version, PDQ-39)
was used. Motor complications, including early
morning akinesia, nocturnal akinesia, end-of-dose
fluctuations,
paradoxical
fluctuations,
and
unpredictable OFFs, were found to significantly
worsen the PDQ-39 Summary Index of patients
with PD. The dimensions of mobility, activities of
daily living, stigma, and communication were most
strongly affected.

Wearing OFF and Delayed ON – Motor
and Non-Motor Fluctuations

NEUROLOGY • August 2015

EMJ EUROPEAN MEDICAL JOURNAL

43

Prof Stocchi described an ongoing study, the Time
to ON Questionnaire in PD (TOQ-PD), which is a
survey being undertaken in PD patients attending
a routine clinical appointment to help characterise
their early morning OFF problems (unpublished
data). This pilot study is a non-interventional,
outpatient study being conducted in 90 consecutive
patients treated in movement disorders centres.
As part of the inclusion criteria, patients, in the
opinion of the prescribing physician, had to be able
to understand and describe the changes in ON and
OFF clinical status. A total of 25% of patients felt
that their medication was taking >1 hour to work.
Almost 52% of patients found it troublesome
when their first daily dose of levodopa took longer
than usual to work (delayed ON), did not work
well (suboptimal ON), or did not work at all (dose
failure). In the case of the mealtime dose of
levodopa, this figure was 56%. Patients also
described a range of problematic symptoms that
occurred while waiting for their levodopa to work,
including slowness, stiffness, and difficulty walking.
Prof Stocchi also recognised the contribution
of peripheral factors to delayed ON and dose
failure with oral levodopa, for example swallowing
difficulties which he clearly illustrated with a series
of endoscopic videos. Swallowing abnormalities
in PD patients include abnormal lingual control of
swallowing, lingual festination, delayed swallowing
reflex (a tendency of parkinsonian patients to
swallow during the inspiration phase increasing
the possibility of aspiration), and repetitive or
involuntary reflux from the vallecula and piriform
sinuses into the oral cavity. These troublesome
symptoms need careful management and
might require a change in the type of food and
diet consumed. Dopaminergic drugs may
improve swallowing; however, alternative routes
of administration such as transdermal therapy,
subcutaneous infusion, or intraduodenal infusion
should be considered.
Gastroparesis, or delayed gastric emptying, is
common in PD, resulting in postprandial fullness,
nausea, vomiting, and impaired drug absorption
that in turn leads to delayed ON or no ON.19
Recently, delayed TTO and dose failures have been
recognised as a significant proportion of total OFF
time, comprising more than twice the duration of
wearing-off in PD patients.20 This was illustrated
clearly in a pharmacokinetic study of levodopa
given every 4 hours undertaken by Prof Stocchi,
which revealed a substantial proportion of OFF
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time over the day, and particularly delayed ON
(unpublished data).
In view of the high prevalence of GI dysfunction in
PD patients and its impact on the efficacy of oral
medication, a range of alternative PD medication
formulations and routes of administration have
been investigated in this setting with varying
degrees of success. These include liquid levodopa,
transdermal dopamine agonists, subcutaneous
apomorphine, and intraduodenal levodopa infusion.
Prof Stocchi also reviewed the strategies that
had been investigated to tackle the phenomenon
of wearing-off.21 Standard oral formulations of
levodopa result in pulsatile dopaminergic
stimulation and are not able to maintain steady
plasma levels throughout the day. Therefore,
continuous dopaminergic stimulation (CDS) has
been proposed to more closely mimic the
physiological situation and help overcome the
motor complications that occur with standard
oral therapy.22-25 Other options include modifying
the timing or formulation of levodopa, modifying
the actions of levodopa by using catechol-Omethyltransferase (COMT) inhibitors (entacapone,
tolcapone), the use of longer-acting dopamine
agonists (such as pramipexole, ropinirole, rotigotine,
apomorphine, or pergolide), or by modifying
the actions of dopamine at the synaptic level
by using a monoamine oxidase B (MAO-B)
inhibitor (rasagiline).
One option for CDS that is backed by considerable
clinical experience is continuous apomorphine
infusion: it has proven efficacy for PD patients
with motor fluctuations that are uncontrolled by
conventional oral or transdermal medication and
is well tolerated. In a recent review, the data for
390 patients from 21 open-label uncontrolled
studies were pooled.26 The results showed a 58.2%
average OFF time reduction (range 38-80%) and
a levodopa-sparing effect with a 45.9% reduction
in levodopa-equivalent dose during an observation
period of 24.8 months (6-57 months). In the case
of dyskinesias, 6 of 11 long-term studies showed
~50% reduction in duration and ~45% reduction
in severity of dyskinesias with continuous
apomorphine infusion.27 Biphasic and peak-dose
dyskinesias showed the best response to therapy.
A study by Prof Stocchi’s own research group
showed a significant and sustained reduction in
the severity of dyskinesias with long-term use of
continuous apomorphine infusion over a period
of 5 years.28

EMJ EUROPEAN MEDICAL JOURNAL

As with all therapeutic interventions, Prof Stocchi
noted that it was important to select the right
patient in order to maximise the success
of treatment. He advised that continuous
apomorphine infusion should be considered in all
PD patients who develop features of complicated
disease irrespective of their age or disease duration.
This should include patients who have become
progressively disabled, those who experience
increasing or long OFF periods, those who have
moderate-to-severe dyskinesias, and those who
are already suffering with motor complications or
who have developed levodopa-induced dyskinesias.
PD patients who might not be suitable for this
treatment option include those with a poor
response to levodopa; those with severe cognitive
impairment; patients with contraindications such
as hepatic insufficiency, pregnancy, or lactation;
patients without support to help them manage
the infusion device; and those with excessive
skin problems.
Prof Stocchi concluded his presentation by
noting that continuous apomorphine infusion has
several advantages over other CDS options for PD
patients who experience motor fluctuations despite
optimised oral medication. Importantly, it is the
least invasive of the three advanced therapies
(apomorphine infusion, intrajejunal levodopa
infusion, and deep brain stimulation) and is
completely reversible. Apomorphine infusion is
practical to use – it can be initiated during inpatient
hospitalisation or in a day-hospital setting – and
does not induce tolerance.28

Apomorphine Penject – AM-IMPAKT
Trial Results and Best Clinical Practice
Professor Stuart Isaacson
Prof Isaacson noted that over the past two
decades the issue of motor fluctuations and OFF
periods in PD patients had focussed very much on
end-of-dose wearing-off of oral PD medication.
However, it is now becoming increasingly
recognised that in addition to end-of-dose wearing
off there are many other contributors to total OFF
time, including nocturnal akinesia, morning akinesia,
postprandial akinesia, delayed TTO, and dose failure
(no ON). Studies have now shown that delayed
TTO is in fact a major contributor to OFF time,
being more than twice the duration of wearingoff.20 He acknowledged that when oral levodopa
is first used to treat PD patients, the clinical effect
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of each levodopa dose is rapid, reliable, and
sustained with an onset of around 20 mins and a
long-duration response. However, with chronic
treatment, the long-duration response is replaced
by a short-duration response and OFF periods,
such as wearing-off and delayed TTO, become
more frequent.
Levodopa has been the recognised ‘gold standard’
treatment for PD for the past 50 years but it is
an oral treatment that must be swallowed and
therefore its efficacy may be affected if the
patient also suffers from GI tract dysfunction. The
GI tract is known to be dysfunctional in many PD
patients and this can occur almost a decade or
more before PD is clinically diagnosed. In addition,
medications used to treat PD may also contribute
to GI dysfunction, including levodopa, dopamine
agonists,
anticholinergics,
amantadine,
and
inhibitors of MAO-B and COMT. GI symptoms, such
as gastroparesis, can impact on the effectiveness
of oral levodopa by delaying its delivery to, and
absorption in, the small intestine,19,29 resulting in
delayed ON or even dose failure.30 Absorption of
levodopa can be affected by competition with
ingested protein for the amino acid transporter.
In addition, recent studies have confirmed a high
prevalence of small intestinal bacterial overgrowth
in PD, which may also affect levodopa absorption,
and have reported an association with poor motor
function, longer daily OFF time, and more episodes
of delayed ON and no ON.31,32
An investigation of the prevalence of delayed
gastric emptying of solids in PD was undertaken
in 22 healthy subjects and 36 patients at different
clinical stages of PD using a 13C-sodium octanoate
breath test (OBT).29 The OBT was able to detect
a significant delay in gastric emptying of a solid
test meal in patients with PD that was associated
with disease severity, illustrating how common
gastroparesis is across all disease stages. While
liquids are able to empty from the stomach quicker
than solids, in PD patients there may still be a delay
in gastric emptying. In the case of oral levodopa,
Doi and colleagues19 demonstrated a significant
relationship between levodopa pharmacokinetics
and gastric emptying in PD patients, suggesting
that delayed gastric emptying is a causative factor
for producing the delayed ON.
The high prevalence of early morning OFF (EMO)
periods has been demonstrated in the results of
the international, multicentre EUROPAR study.33
EMO periods occur when the first morning dose
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of oral levodopa has a delayed onset of action and
were found in this study to be present in 59.7% of
the 320 patients, occurring throughout the course
of PD in mild, moderate, and severe disease. Prof
Isaacson highlighted that EMO periods are often an
early sign of emerging motor fluctuations and the
loss of the long-duration levodopa response, and
can occur despite attempts to optimise oral
therapy and the use of multiple medications.
During episodes of morning akinesia the patient
can experience impaired mobility and function until
the oral levodopa takes effect, and this is known to
have a negative effect on patient QoL.18 Although
morning akinesia represents the motor component
of EMO periods, both motor and NMS are frequent
in PD patients at these times.
A range of treatment strategies have been
employed in an attempt to resolve the issue of
morning akinesia, for example the use of long-

acting dopamine agonists or MAO-B inhibitors, or
by aiming to improve delivery of levodopa to the
proximal small intestine by using liquid, dispersible,
modified, or higher-dose levodopa. However, none
of these approaches addressed the problem of PD
patients who have gastroparesis where emptying
of both solids and liquids may be impaired,29 and
in whom a delayed onset of levodopa effect may
still occur. This has been illustrated in a study
by Chaná and colleagues,30 who assessed the
pharmacokinetics of levodopa in 19 patients with
advanced PD with and without a delayed onset
of first levodopa dose in the morning. The
results confirmed that the difference in plasma
concentrations of levodopa between the two
groups was most likely due to delayed gastric
emptying, and this phenomenon probably underlies
the delayed clinical response to oral levodopa in
many PD patients.30

Mean ± SD time to ON (minutes)

Figure 3: Apomorphine pen injection.
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Figure 4: Change from baseline in time-to-ON following apomorphine injection: results of AM-IMPAKT
[unpublished data].
SD: standard deviation; vs: versus.
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These problems highlight the need to consider
non-oral therapies to manage motor symptoms
in this setting. The potent dopamine agonist
apomorphine administered subcutaneously has
provided clinicians with an effective option for the
rapid resolution of the parkinsonian symptoms
for over 25 years. Prof Isaacson considered that
subcutaneous apomorphine intermittent injection
offered an easy and practical therapeutic option
for managing EMO as it avoided the oral route of
administration that could be affected by delayed
gastric emptying or impaired intestinal absorption.
The clinical efficacy of apomorphine infusion
has been confirmed in a range of randomised,
controlled clinical trials undertaken in the USA. In
the APO202 study of 29 PD patients with motor
fluctuations and prolonged OFF time despite
aggressive oral therapy, apomorphine injection
was able to reverse 95% of OFF episodes over a
4-week period when used as needed.34 The APO302
study undertaken in 62 patients at 26 USA centres
demonstrated that apomorphine injection was
able to achieve rapid and reliable improvements in
UPDRS motor scores compared with placebo.35
These
significant
improvements
in
mean
UPDRS motor scores were seen 20 mins after
administration of apomorphine injection. In
addition, apomorphine injection significantly and
rapidly improved mobility as early as 7.5 mins after
dosing, and this effect persisted for at least 40 mins
after dosing. Apomorphine injection was found
to be effective over the long term, with efficacy
being maintained in patients with an average
therapy duration of 14.5 months. The APO303
study of 56 apomorphine-naïve patients with
advanced PD at 17 USA centres provided further
confirmationof the ability of apomorphine
injection to provide rapid, effective relief of OFF
episodes in PD patients already receiving
optimised oral medication.36 Mean changes from
pre-dose in UPDRS motor were significantly
improved following apomorphine injection (4 mg)
versus placebo at 20 mins (p=0.0002), 40 mins
(p<0.0001; maximum improvement), and 90 mins
(p=0.0229) post-administration.
Prof Isaacson described how the use of
apomorphine pen injection (Figure 3) has been
investigated in the recently completed Phase IV,
10-centre, open-label, efficacy and safety study –
AM-IMPAKT (Apokyn for Motor IMProvement of
morning AKinesia Trial).37-39 AM-IMPAKT aimed to
investigate whether subcutaneous apomorphine
injection given upon awakening was able to provide
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rapid and reliable improvement in motor symptoms
in PD patients with morning akinesia due to
delayed onset of the first oral levodopa dose. During
the 7-day baseline study period, each morning
following their first oral levodopa dose, patients
recorded their TTO in a diary every 5 mins for up
to 60 mins by checking boxes either ‘yes’ or ‘no’
until onset of ON. Patients subsequently initiated
treatment with the apomorphine pen and used this
for another 7 days upon awakening, completing the
same TTO diary each morning. The primary endpoint
was a comparison of TTO between the levodopa
study period and the apomorphine injection period.
Morning akinesia was found to be common in the
study population and occurred throughout the
course of PD, even at relatively early stages. Over
half of the PD patients who entered the study were
in the first decade of their disease and, despite a
range of oral therapies, had experienced persistent
morning akinesia for an average of 4 years.
The final analysis of data for 88 patients found that
apomorphine pen injection significantly improved
the primary endpoint of TTO: mean baseline
TTO with levodopa averaged 60.64 mins, which
reduced significantly to a mean of 23.95 mins with
apomorphine injection (p<0.0001; Figure 4),
representing a mean change from baseline of
36.7 mins. UPDRS motor scores were also
significantly reduced within 15 mins of apomorphine
compared with baseline (35.5 versus 17.3;
p<0.0001), representing a mean change in UPDRS
score of 18.2.
Analysis of individual data for each patient was
very revealing and demonstrated the reliability
of the response to apomorphine injection.
Approximately 98% of patients experienced a
rapid and robust clinical improvement in TTO with
apomorphine injection. Dose failures were found to
be common during the levodopa baseline period;
however, most of these patients achieved an ON
state with apomorphine injection, the majority
within 20 mins.
Significant improvements were also found for the
secondary patient-reported outcomes following
treatment with apomorphine injection. Patients
and investigators were asked to rate their global
impression of severity of illness relative to akinesia/
motor function before and after apomorphine
therapy, measured on a 7-point scale from
‘normal’ to ‘extremely ill’. In both cases significant
improvements were recorded (p<0.0001). Measures
of health-related QoL also showed improvement
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with apomorphine injection. EQ-5D-3L is a patientreported health outcome scale related to mobility,
self-care, usual activities, pain/discomfort, and
anxiety/depression, and each dimension is ranked
from 1 (no problem) to 5 (extreme problem), so
lower scores indicate a more favourable rating.
EQ-5D-3L index scores were significantly reduced
from a mean of 3.30 at baseline to a mean of 2.18
at the end of the 1-week apomorphine treatment
period (p<0.0001). Using the EQ-5D Visual
Analogue Scale, subjects rate their health
state relative to akinesia on a scale of 0 (worst
imaginable) to 100 (best imaginable), so higher
scores indicate a more favourable rating. In
AM-IMPAKT, scores also showed significant
improvement from a mean of 50.38 at baseline to
65.67 at the end of the apomorphine treatment
period (p=0.0001). An exploratory analysis of the
number of patients who had at least one dose failure
(failure to turn ON within 60 mins) found a total
of 46% of patients during the levodopa baseline
period compared with 7% during apomorphine
injection period.
Prof Isaacson concluded by highlighting the
importance of addressing not only end-of-dose
wearing-off but also delayed TTO in PD patients,
since this comprises the majority of total OFF time.
Commonly, oral levodopa onset is impaired or
absent due to GI dysfunction and therefore there

is a need for effective non-oral PD medication to
return patients to the ON state quickly. Results
from the AM-IMPAKT study confirm that morning
akinesia is a common but under-recognised
symptom of PD and that subcutaneous
apomorphine pen injection meets the need for
an effective, rapid, and reliable solution to this
problem. Notably, the observed reduction in
TTO in the study is clinically relevant since there
were significant improvements across a range of
subjective measures, including UPDRS motor scores,
QoL, and clinician and patient global impression
of severity.

Summary
Prof Trenkwalder concluded the symposium by
noting that an Expert Consensus Group Report
on the use of subcutaneously administered
apomorphine for the management of PD had just
been accepted for publication in Parkinsonism
& Related Disorders. The publication provided
both a review of the published literature on
the use of apomorphine and also consensus
recommendations prepared by 26 advisors from
13 countries to help guide healthcare professionals
in the optimal application of apomorphine therapy
in clinical practice.
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